Group 1 - The core viewpoint of the news highlights the recent performance of Emperor International Investment, which saw a significant increase in stock price despite a substantial decline over the past month and year [1][2] - As of May 9, the Hang Seng Index rose by 0.4% to 22,867.74 points, while Emperor International Investment's stock price increased by 20.69% to HKD 0.035 per share, with a trading volume of 54 million shares and a turnover of HKD 2.08 million [1] - Financial data indicates that for the period ending September 30, 2024, Emperor International Investment reported total revenue of HKD 33.53 million, a decrease of 55.43% year-on-year, and a net profit attributable to the parent company of -HKD 1.43 million, down 193.74% year-on-year [1] Group 2 - Currently, there are no institutional investment ratings for Emperor International Investment, and its price-to-earnings (P/E) ratio stands at 4.28 times, ranking fifth in the pharmaceutical and biotechnology industry, which has an average P/E ratio of 5.44 times [2] - The company specializes in precision oncology and genetic testing, providing molecular diagnostic solutions and academic research services for clinical doctors, hospitals, cancer patients, and high-risk health groups [3] - Emperor International Investment's subsidiary, Lianhe Medical, has developed genetic testing products covering various types of tumors and adheres to strict quality management systems, achieving high scores in multiple assessments [3]
帝王国际投资(00928.HK)5月9日收盘上涨20.69%,成交208.06万港元